(833) 317-6278 
By: Angus Liu
AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) with the FDA.
Twitter bio
Biopharma follower @FiercePharma & @FierceBiotech . Medill MSJ 16
Angus Liu
Geo Focus
Coverage Attributes:
Beta
Press Release:
43
%
Cites Data:
38
%
Government Announcement:
10
%
Private Sector Announcements:
4
%
Themes Covered:
Not enough data
Pitching Insights
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
